Full-Time

Senior Manager

Competitive Intelligence, Oncology

Posted on 11/23/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

Hybrid

Category
Biology & Biotech (2)
,
Requirements
  • Doctorate degree 6 years of Strategy/Management Consulting, Competitive Intelligence, or Equity Research experience
  • Masters degree and 8 years of Strategy/Management Consulting, Competitive Intelligence, or Equity Research experience
  • Bachelors degree and 10 years of Strategy/Management Consulting, Competitive Intelligence, or Equity Research experience
Responsibilities
  • Be a strategic thought partner to key collaborators across disease area, brand, corporate, and other cross-functional teams supporting Amgens OBU.
  • Synthesize information from multiple sources to develop strategic insights and point of view on key competitive developments, implications to Amgen and actions Amgen must take.
  • Work in a highly cross functional manner and manage changing priorities across several key customers.
  • Develop productive relationships with Global and Regional teams to define business problems and develop integrated analysis plans based on standard methodologies.
  • Apply structured problem solving to collect, analyze and report CI, incorporating primary and secondary data sources to generate meaningful insights.
  • Articulate and educate customers on the relevant impact of changing market dynamics to their business from a CI perspective.
  • Organize and facilitate strategic exercises & competitive simulations to generate competitive insights and company plans.
  • Coordinate and facilitate CI collection efforts at major medical conferences/congresses.
  • Manage a network of primary data sources, including vendors and Amgen employees, to enable effective project delivery.
  • Assess the reliability of CI research findings, maintaining high standards for accuracy, relevance, and quality in deliverables at all times and communicate level of evidence to key partners.
  • Present on a regular basis in-depth analyses and summaries of results, interpreting and communicating results with recommendations to key stakeholders.
  • Work to grow competitive intelligence/strategy to support other functions in the organization.
  • Abide by and strictly enforce Amgens CI Legal and Ethical Guidelines with internal colleagues and agencies.
  • Some travel (15-20%) required.
Desired Qualifications
  • Doctorate degree and 9 years of Strategy/Management Consulting, Competitive Intelligence, or Equity Research experience
  • Masters degree and 11 years of Strategy/Management Consulting, Competitive Intelligence, or Equity Research experience
  • Bachelors degree and 15 years of Strategy/Management Consulting, Competitive Intelligence, or Equity Research experience
  • Advanced degree (MS/MBA/PhD) with a focus on life sciences and business
  • Experience with previous competitive intelligence role through agency and/or biopharma experience
  • Leadership and stakeholder management experience is strongly preferred
  • Experience working in global pharma/biotech industry and in-depth understanding of US/Canada/EU5 major markets drug development pathways is strongly preferred
  • Relevant experience in oncology via prior project work, disease area knowledge, marketing/sales experience, etc.
  • Prior experience in strategy/management consulting in the biopharma industry preferably through a lead role
  • Prior experience as an equity research analyst within the biopharma industry
  • Consistent track record of influencing key business decisions through thoughtful insights and recommendations
  • Demonstrated ability to think strategically and analyze data to support critical business decisions
  • Excellent oral, written, and presentation skills—able to explain complex concepts clearly to a variety of audiences
  • Evident project management skills—able to manage multiple, simultaneous projects and data sources
  • Demonstrated analytical skills—understands the advantages and limits of different analytical approaches and studies
  • Ability to work collaboratively in team-based environment
  • Strong understanding of the latest developments and trends in the oncology space, key competitive dynamics and unmet medical needs
  • Understanding of at least one other functional area in CD&A (forecasting, market research, and secondary analytics)
  • Experience in insights generation for the biopharmaceutical (or other healthcare) industries

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE